WE COLLABORATE WITH PHARMACEUTICAL COMPANIES TO ACCELERATE PATIENT’S ACCESS TO NOVEL THERAPIES

FACTS

14 CLINICS In 8 countries in Europe,
North America and Africa
MORE...
15 TO 60 DAYS Fast start-up/regulatory
timelines
MORE...
5 TO 30-FOLD Patient enrollment
vs competition
MORE...
9 TO 24 MONTHS PROOF-OF-CONCEPT MORE...

DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

The pharmaceutical industry is under increased pressure to advance development of new therapies in a fast and efficient manner, whilst ensuring safety and quality of data.

ARENSIA’s playing field

A critical segment of the drug development process is the PROOF OF CONCEPT phase, namely the „first-in-patient“ (Phase IB or IIA) clinical trials which aim to detect the first efficacy signal of new therapies in the given targeted patient population/disease.

The data resulting out of the PROOF-OF-CONCEPT trials are the foundation for deciding on whether to stop or to continue the research of new therapeutic options before making any large investments to advance the drugs to later phases of development.

Industry challenge

An increasing number of clinical trials need expert research facilities able to manage sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in patient populations. Their protocols imply complex medical assessments, intensive PK/PD procedures and require a strong infrastructure for hospitalization.

The typical clinical trial sites are lacking dedicated personnel, and this personnel often lacks expertise to execute such complex research. As a consequence, to perform PROOF OF CONCEPT clinical trials (which require relatively low numbers of patients, ranging 12 to 200), pharmaceutical companies must involve a multitude of clinical trial sites to compensate these shortcomings. High costs, delays and quality issues ensue.

ARENSIA solution

At ARENSIA, we understood industry needs, and to meet them, we have built over the last decade our proprietary network of research clinics in 8 countries, serving numerous therapeutic areas.

All ARENSIA Clinics are entirely dedicated to speeding up PROOF OF CONCEPT trials, and have all systems in place to ensure highest safety standards for patients, as well as quality of data.

Typical clinical trial sites are overcrowded by daily hospital duties, lack of staff (especially research-oriented personnel), competition for same populations and long timelines for contract negotiations. ARENSIA Clinics achieve a remarcable time reduction through unrivalled recruiting performance! The shortened time and the different setup of concentrating effort on few ARENSIA Clinics (instead of the traditional high number of sites) lead to an overall budget reduction of at least 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial.

93% repeat business proves that ARENSIA’s value proposition is the long expected disruptive break-through in time and cost! This has allowed our continuous growth, while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, as well as global CROs.

WATCH THIS VIDEO Find out more about us in 2 minutes

WHAT OUR SPONSORS SAID

In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.

Leading Global Pharmaceutical Company, US based

We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.

Mid-Size Biotech Company, US based

We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.

Leading Global CRO, US based

NEWS

INNOVATIONXCHANGE SUMMIT PLATFORM BY ARENSIA INNOVATIONXCHANGE SUMMIT PLATFORM BY ARENSIA 18.09.2023

ARENSIA is delighted to introduce its latest face-to-face summit platform: INNOVATIONXCHANGE! On November 6th, we will inaugurate our first event a...

READ MORE
ARENSIA CLINICS SPEED UP NEURO-PSYCHIATRIC TARGET EXPLORATION! ARENSIA CLINICS SPEED UP NEURO-PSYCHIATRIC TARGET EXPLORATION! 11.09.2023

Neuroscience clinical trials thrive on a diverse range of factors such as novel target identification methods, comprehensive AI integration, real-worl...

READ MORE
WE EXPANDED OUR CLINIC IN TBILISI, GEORGIA! WE EXPANDED OUR CLINIC IN TBILISI, GEORGIA! 14.07.2023

ARENSIA Clinic in Tbilisi has expanded its facilities to 800 sqm and its staff to 50 FTEs, with more medics and more nurses - proof of our commitment ...

READ MORE
 “CLINICAL TRIALS IN UKRAINE” CONFERENCE “CLINICAL TRIALS IN UKRAINE” CONFERENCE 30.06.2023

Fantastic event and vivid discussions at yesterday’s “Clinical Trials in Ukraine” conference. We are thankful to the host, The Minis...

READ MORE
UKRAINE RECOVERY CONFERENCE. RECEPTION EVENING UKRAINE RECOVERY CONFERENCE. RECEPTION EVENING 22.06.2023

Following a successful day at Ukraine’s Recovery Conference in London, a delightful evening at the reception at Lancaster House! Our CEO, D...

READ MORE
UKRAINE RECOVERY CONFERENCE UKRAINE RECOVERY CONFERENCE 21.06.2023

ARENSIA stands with Ukraine! - from day one of the Russian invasion back in February 2022. Not with words, but with deeds! We are proud that the pheno...

READ MORE
PHARMACEUTICAL FORUM CLINICAL TRIALS IN UKRAINE PHARMACEUTICAL FORUM CLINICAL TRIALS IN UKRAINE 20.06.2023

ARENSIA is thrilled to exhibit in person at the “Clinical Trials in Ukraine” conference, taking place in Kyiv on Thursday, June 29.&n...

READ MORE

We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse
CONTACT US